Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

about

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

Item

http://www.wikidata.org/entity/Q57252649

description

article

@en

im Oktober 2014 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2014

@uk

name

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@en

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@nl

type

Item

label

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@en

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@nl

prefLabel

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@en

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@nl

P1476

Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells

@en

P2093

Akhil Chopra

http://www.w3.org/2001/XMLSchema#string

Cher Heng Tan

http://www.w3.org/2001/XMLSchema#string

Christopher B. Howard

http://www.w3.org/2001/XMLSchema#string

Christopher J. de Bakker

http://www.w3.org/2001/XMLSchema#string

Jakob W. Buecheler

http://www.w3.org/2001/XMLSchema#string

Martina L. Jones

http://www.w3.org/2001/XMLSchema#string

Sierin Lim

http://www.w3.org/2001/XMLSchema#string

Stephen Goodall

http://www.w3.org/2001/XMLSchema#string

Stephen M. Mahler

http://www.w3.org/2001/XMLSchema#string

Tao Peng

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic nanoparticles for drug delivery in cancer

Trimer-based design of pH-responsive protein cage results in soluble disassembled structures.

Isolating a trimer intermediate in the self-assembly of E2 protein cage.

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.

Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.

Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.

EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise.

P304

1230-1236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCTB.4545

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P921

nanoparticle

biotechnology